END-VOC
European and Global Response to COVID-19 pandemic and variants of concern
Objective
Elucidate the global circulation of the current and emerging SARS-CoV-2 VOCs and their characteristics, including transmissibility, pathogenicity and propensity to cause reinfection, to support best control strategies and the development of diagnostics; evaluate the impact of VOCs on the effectiveness of different vaccines and vaccination strategies; and assess the implications of VOCs on the choice of optimal treatment options. END-VOC will also investigate how VOCs alter long-term post-infection sequelae and where new VOCs emerge within hosts using our clinical cohorts.
Description
The END-VOC consortium consists of 19 partners with cohorts in Europe (UK, Spain, Italy, Germany, Netherlands, Norway, Luxembourg, Switzerland), South America (Brazil and Peru), Africa (Mozambique, South Africa, Nigeria and 13 countries in the ANTICOV trial), Middle East (Palestine) and Asia (India, Pakistan, Philippines). By using data from 28 well-established cohorts in these countries, the three-year project will focus on five key areas: i) detect and characterize emerging viral variants; evaluate their capacity to ii) evade vaccine-induced immunity or cause reinfections, iii) escape current treatments, iv) cause Long Covid; as well as v) provide recommendations to better prepare and respond to future infectious disease outbreaks.
AIGHD Research Lead
Dr. Anniek de Ruijter
Partners
University College London, United Kingdom (Lead)
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Italy
Università Degli Studi Di Milano, Italy
Universitatsklinikum Heidelberg, Germany
Instituto de Salud Global de Barcelona, Spain
Institut Universitari per la Recerca a l’Atencio Primaria de Salut Jordi Gol i Gurina, Spain
Folkehelseinstituttet (Norwegian Institute of Public Health), Norway
Stichting Amsterdam Institute for Global Health and Development (including UvA Law Centre for Health and Life), The Netherlands
Nigeria Centre for Disease Control Universite de Geneve, Switzerland
Public Health Foundation of India Fundaçao Oswaldo Cruz, Brazil
Laboratoire National De Santé, Luxembourg
Arab American University Palestine
Institut D’investigació En Ciencias De La Salut Germans Trias I Pujol, Spain
Dopasi Foundation, Pakistan University of The Philippines
Centro de Investigaçao em Sañude de Manhiça, Mozambique
Drugs for Neglected Diseases Initiative, Switzerland
Funders
European Commission
Countries
The Netherlands
Spain
Switzerland
Mozambique
The Philippines
Brazil
Luxembourg
Norway
Germany
Italy
United Kingdom